North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-05-01 Anti-obesity drugs acting on the gastro-intestinal tract
| Orlistat |
|
Formulary
|
|
 MHRA Drug Safety Update (March 2014): Orlistat: theoretical interaction with antiretroviral HIV medicines |
|
| Naltrexone/ bupropion Mysimba® |
|
Non Formulary
|
|
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity |
|
Links
- MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs
- MHRA Drug Safety Update (March 2014): Orlistat: theoretical interaction with antiretroviral HIV medicines
NENC ICB Tier 3 Weight Management Commissioning Statement - NENC Palliative and End of Life Care Symptom Control Guidelines
- NICE NG246: Overweight and obesity management
- NICE NG62: Cerebral palsy in under 25s: assessment and management
- NICE TA494: Naltrexone–bupropion for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV Safe Transfer of Prescribing Guidance
- Tier 3 Weight Management Commissioning Statement